% | $
Quotes you view appear here for quick access.

Wilhelmina International, Inc. Message Board

joemo36 71 posts  |  Last Activity: Oct 5, 2015 8:09 PM Member since: May 21, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    time to buy is now meeting this weekend

    by joemo36 Oct 2, 2015 1:02 PM
    joemo36 joemo36 Oct 5, 2015 8:09 PM Flag

    not yet

  • whatever buy now

  • buy it now if you can

  • Reply to

    meeting with DF on friday

    by joemo36 Sep 9, 2015 6:21 PM
    joemo36 joemo36 Sep 23, 2015 5:02 PM Flag

    left message for dean he called me back and told me.

  • rst Webinar for Wound Care Professionals to be held September 15th at 1:00 p.m. Eastern on

    GAITHERSBURG, Md., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (NUOT), a pioneer in biodynamic therapies, today announced it has launched a series of educational tools designed to aid wound care centers in making the transition from ICD-9 to ICD-10 in advance of the October 1st 2015 implementation date, as mandated by the Centers for Medicare & Medicaid Services (CMS).

    A graphic accompanying this release is available at

    These tools, created by the reimbursement experts at Nuo Therapeutics and their partners, include:

    Wound Care Reimbursement Code Converter
    Educational Webinar for Wound Care Professionals
    Accredited Online Wound Care Education Series for Billers and Coders
    "As the U.S. healthcare system moves from a fee-based model to a performance-based model, a hospital's ability to demonstrate quality outcomes will continue to increase in importance," said Dean Tozer, President and Chief Executive Officer of Nuo Therapeutics. "Proper coding is key to this effort, and as the ICD-10 transition nears, we saw an opportunity to take a leadership position in helping educate healthcare providers, billers and coders on the many, complicated and nuanced matters related to the new wound care coding and reimbursement landscape."

    Wound Care Reimbursement Code Converter

    The "Wound Care Reimbursement Code Converter" assists billers and coders in converting ICD-9-CM wound care codes to the ICD-10-CM equivalents. In addition, the Converter offers the ability to do a reverse look-up of the ICD-9-CM code associated with the new ICD-10-CM codes.

    The tool is available online at or as a pocket guide, which may be obtained from a Nuo Therapeutics representative.

    Educational Webinar for Wound Care Professionals

    Related Quotes
    Nuo Therapeutics, Inc. Watchlist
    OTC MarketsFri, Sep 11, 2015 2:57 PM EDT

    NUO THERAPEUTICS, INC. Financials EDGAR Online Financials 17 days ago
    NUO THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online 1 mth 1 day ago
    Nuo Therapeutics has partnered with HMP Communications to host an educational webinar during which wound care physician, Dr. Bob Bartlett, MD, FAPWHc, CME, FACEP, UHM and Chief Medical Officer of Restorix Health, Inc., along with wound care reimbursement expert, Linda Martien, CPC, COC, CPMA of Nuo Therapeutics, will review the new charting requirements under ICD-10 and what its implementation will mean specifically for wound care professionals. In addition, the speakers will highlight several examples of diagnostic coding in wound care under ICD-10 as it compares to ICD-9.

    The webinar, titled "DE-CODING THE CODE: Solutions for a Smooth Transition to ICD-10 for Wound Care Professionals," will be available at 1:00 p.m. Eastern on Tuesday, September 15th and Thursday, November 5th, respectively, with a live question and answer session following each event. To register, please visit:

    Accredited Online Wound Care Education Series for Billers and Coders

    As the Company previously announced, it has partnered with AAPC to launch a series of accredited interactive modules focusing on key topics in wound care and the coding and billing of treatments in this specialty area.

    The first module, Wound Care 101, is focused on providing billers and coders a foundational knowledge of wound care, and is now available for registered users on the AAPC Learning Management System. The second module in this series, Wound Care 201, which will incorporate education on ICD-10 coding, is expected to launch later this year. Participants will be eligible to receive continuing education credits toward their AAPC certification.

    About the Transition to ICD-10

    Coding under ICD-10 will require healthcare professionals to adhere to a much higher level of specificity and accuracy when transcribing and coding their patients' diagnoses and procedures than under ICD-9. In ICD-10, there are ten times more codes for diabetic foot ulcers, venous leg ulcers and pressure ulcers, alone, aimed at generating a clearer picture of patient care and outcomes and, in turn, more accurate reimbursement from both private and public payers.

    CMS has created several online resources to help healthcare providers jumpstart their transition to ICD-10, including a Quick Start Guide and a Road to 10 online resource or small practice physicians.

    For more information on the differences between ICD-9 and ICD-10 as it relates to wound care, Nuo Therapeutics has also created a guide:

  • Reply to

    meeting with DF on friday

    by joemo36 Sep 9, 2015 6:21 PM
    joemo36 joemo36 Sep 10, 2015 10:22 AM Flag

    you welcome

  • Reply to

    meeting with DF on friday

    by joemo36 Sep 9, 2015 6:21 PM
    joemo36 joemo36 Sep 10, 2015 10:07 AM Flag

    yes they told me that last Friday.

  • will find out soon

  • Regenerative medicine company Advanced BioHealing is now part of Shire (NASDAQ:SHPGY), but before it was acquired last May, the Westport, Connecticut company was hours from pulling the trigger on an initial public stock offering.

    ABH’s wound healing product for diabetics had made the company profitable in less than three years, but it needed more cash. Dermagraft is a bioengineered skin substitute product consisting of human fibroblast cells on a scaffold. The product is used to treat diabetic foot ulcers. With Dermagraft sales growing, ABH executives last year concluded that they needed to build a second manufacturing facility at a cost of up to $100 million, said Dean Tozer, ABH’s senior vice president of corporate development. ABH was founded in 2004 and had raised $10.4 million in two rounds of venture financing. But the company’s investors were looking for an exit.

    Tozer said that discussions with private equity firms came close to a deal. But in the second half of 2010, management decided to pursue an IPO. The offering would have valued the company at more than $600 million. But on the morning of May 17, the day before ABH was expected to go public, the company instead announced it had been acquired by Shire for $750 million.

    Tozer spoke Tuesday in Chapel Hill, North Carolina at medtech11, the annual conference hosted by North Carolina medical technology group ibiliti. It was the first time he had spoken publicly since the company’s acquisition by Shire.

    The theme of medtech11 is “convergence” and Tozer offered insight on navigating through the regulatory process a product that is part medical device and part biological. He also offered tips on commercialization. Here are some highlights:

    Forget what you know. The U.S. Food and Drug Administration considers Dermagraft a device. The Centers for Medicare & Medicaid Services considers the product a biologic. European regulators classify it as a medicinal product. You can’t think about your product as being in a single category. You’ve got to be able to think about all of them. So Tozer’s advice is to forget what you know. “If your product is a convergence product, it doesn’t apply.”

    Find the right people. Because Dermagraft doesn’t fall into a single category, ABH needed to find the right people who could talk to the FDA and CMS. Finding the right people was also important for sales. The company established strong incentives for sales growth and the team met them. Since Dermagraft’s 2007 launch, sales had grown to $147 million in just three years.

    Leverage. ABH was in the enviable position to choose between either an IPO or a sale. With growing revenue and more than $35 million in profit, the company was a strong IPO candidate. Shire entered the picture late in the game in the weeks before the company was set to enter the public markets. “The leverage we got was a viable IPO ready to go,” Tozer said. The Shire deal was done in 19 days. Tozer said the company chose to be acquired by Shire because of the volatility of the market.

    Show them the money. Companies increasingly must show the economic value of their technology. Clinical trial data is important not only to make the scientific case for a product, it can also make an important economic point to payers. Payers want to see how a new product will avoid cost when compared with the standard of care. “It’s really starting to affect how trials are designed,” Tozer said.

    More on clinical trials. ABH did a retrospective data analysis that showed that Dermagraft is cost effective after six months. That’s important to payers because their data show that people typically change insurance every two years. If a product doesn’t avoid cost before then, it won’t save the payer money.


  • joemo36 by joemo36 Aug 23, 2015 9:55 PM Flag

    Jason Napodano, CFA ‏@JNapodano Aug 18
    @darrenestes @b_miga88 Next step is to expand the VA business and try to get to a scalable model with the VA, then fix CMS/CED issues.
    0 retweets 0 favorites
    Reply Retweet Favorite

  • joemo36 by joemo36 Aug 23, 2015 9:54 PM Flag

    Jason Napodano, CFA ‏@JNapodano Aug 18
    @b_miga88 @darrenestes Let them negotiate with Deerfield and let's see what the terms are. I think they come to terms, but can't say what $.
    0 retweets 0 favorites
    Reply Retweet Favorite

  • will get it done

  • Reply to

    Plausible scenarios

    by chitownstockpicker Aug 17, 2015 12:52 PM
    joemo36 joemo36 Aug 17, 2015 1:03 PM Flag

    they will get it done trust dean very smart man

  • Reply to


    by cmezu Aug 17, 2015 12:38 PM
    joemo36 joemo36 Aug 17, 2015 12:49 PM Flag

    i agree

  • he knows he can get it done

6.45+0.41(+6.88%)Oct 6 1:00 PMEDT